Elisabet de los Pinos, CEO of Aura Biosciences Inc. (NASDAQ:AURA), recently sold 24,992 shares on October 18 for about $300,838 at an average price of $12.04 each. This sale was part of a pre-arranged trading plan from June 2023. After the sale, she still owns 329,847 shares directly and 131,412 shares through a trust.
Aura has reported positive Phase 1 trial results for its drugs AU-011 and bel-sar for bladder cancer, showing high rates of complete clinical responses. Investment firms like TD Cowen and Scotiabank have upgraded their ratings and price targets for the company. Aura is moving to Phase 2 trials and is in talks with the FDA. Financially, Aura is strong, with an estimated $165 million in cash to last until mid-2026. There’s also a new interim CFO, Amy Elazzouzi, after Julie Feder’s departure.
InvestingPro Insights
Despite the stock being on the rise—29.3% in the past week and 63.28% in the last six months—Aura is not yet profitable, with a negative P/E ratio of -7.2 and an operating loss of $90.35 million. However, it has more cash than debt, giving it some financial breathing room. Note that Aura does not pay dividends, typical for biotech firms. With a market cap of $510.45 million, it is still in a growth phase.
InvestingPro provides 11 more insights into Aura Biosciences, useful for potential investors.
This article was AI-generated and reviewed by an editor. For more details, see our T&C.
`
